3 Stocks Worth Staying Updated On: VYNE Therapeutics (VYNE), Scinai Immunotherapeutics (SCNI), Cardiol Therapeutics (CRDL)

The biotech and healthcare sectors continue to generate interest amid ongoing advances in clinical research, product development, and emerging therapeutic innovation. Companies demonstrating progress across regulatory, operational, and commercialization efforts are increasingly drawing investor attention as the industry navigates evolving market conditions.

VYNE Therapeutics Inc (VYNE)

VYNE Therapeutics Inc (NASDAQ: VYNE) opened trading on May 21, 2026, with great promise as it jumped 0.19% to $0.68. During the day, the stock rose to $0.68 and sank to $0.66. Taking a more long-term approach, VYNE posted a 52-week range of $0.28-$1.96.

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 66.27%. Meanwhile, its Annual Earnings per share during the time was 66.27%.  This publicly-traded company’s shares outstanding now amount to $33.35 million, simultaneously with a float of $31.44 million. The organization now has a market capitalization of $22.61 million.

Scinai Immunotherapeutics Ltd ADR (SCNI)

Scinai Immunotherapeutics Ltd ADR (NASDAQ: SCNI) started the day on May 21, 2026, with a 4.00% increase to $0.5. During the day, the stock rose to $0.51 and sank to $0.44. Taking a long-term approach, SCNI posted a 52-week range of $0.44-$6.18.

It was noted that the giant of the Healthcare sector posted annual sales growth of 21.04% over the last 5 years. Meanwhile, its Annual Earnings per share during the time was 21.04%.  This publicly-traded company’s shares outstanding now amount to $3.47 million, simultaneously with a float of $3.39 million. The organization now has a market capitalization of $1.72 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to build a broader cardiovascular growth strategy through the development of next-generation therapies aimed at large and underserved disease markets. By expanding beyond recurrent pericarditis, the company is positioning itself to address chronic cardiac conditions where inflammation and fibrosis contribute significantly to disease progression.

Market Momentum

As of May 21, 2026, CRDL closed at $1.31, up 0.77%, with trading volume of 286,669 shares compared to an average volume of 672,769 shares. The company currently maintains a market capitalization of $151.007M and a beta of 0.43, reflecting relatively moderate volatility for a small-cap biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.33 suggests substantial upside potential tied to future pipeline advancement and clinical milestones.

Pipeline Development: CRD-38

Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy is intended to target inflammation and fibrosis, biological mechanisms strongly associated with worsening cardiac function and progressive heart disease.

Large Market Opportunity

Heart failure remains one of the largest cardiovascular markets globally, affecting millions of patients and generating substantial healthcare costs annually. Despite multiple approved therapies, unmet need persists for treatments capable of directly addressing inflammatory and fibrotic pathways associated with disease progression and long-term cardiac decline.

Outlook

As CRD-38 advances toward future clinical development, the program could emerge as an important secondary value driver for Cardiol. Continued progress across the broader pipeline may strengthen the company’s strategic positioning within cardiovascular biotechnology.